Question explored with the scientific record
Is long term use of Carbimazole safe
The short version: long-term carbimazole is a trade-off between a real but small risk of serious early harm and a well-documented long-term safety record, but the evidence base is thin and mostly comes from one group.
The evidence for long-term safety comes almost entirely from one Italian research group's narrative review of their own patients [10]. They report that serious adverse events after the first year are very rare: only 6 out of 140 total events happened after year one, and 5 of those were minor [10]. That sounds good, but it is a single-center review, not a large independent trial. The same review claims long-term methimazole (carbimazole's active form) is not inferior to radioactive iodine and may even be better for cholesterol, mood, and heart function [10]. The confidence in those claims is limited by the source.
The real danger is agranulocytosis, a near-total loss of infection-fighting white blood cells. It happens in about 0.1 to 0.4 percent of patients, almost always in the first three months [7, 8]. The evidence includes multiple case reports of women who developed this complication within weeks of starting the drug, with neutrophil counts dropping to zero [2, 4, 5, 6]. One patient needed a 12-day hospital stay for severe facial infection [2]. Another developed simultaneous liver injury [3]. The risk is dose-related and higher at the starting doses used to bring hyperthyroidism under control [8]. Once you survive the first year, the risk of this complication drops dramatically.
| Risk | Timing | Approximate rate |
|---|---|---|
| Agranulocytosis (dangerous low white blood cells) | First 3 months | 0.1–0.4% of patients [7, 8] |
| Liver injury (usually mild, resolves) | First 3 months | 0.04–0.08% [8] |
| Any serious adverse event after year one | After 12 months | Very rare (4% of all events) [10] |
The evidence does not include a single large, independent, long-term randomized trial comparing carbimazole to placebo or to no treatment. The safety data after year one is thin and comes from a small number of patients followed by the doctors who advocate the treatment. The burden of proof for a lifelong drug is higher than what is presented here.
My call: long-term carbimazole is reasonably safe for most people once you get past the first few months, but the evidence base is weaker than it should be for a drug taken for years. Confidence: moderate.
Sources used 8
-
Pseudomonas aeruginosaEcthyma Gangrenosum and Facial Cellulitis Complicating Carbimazole-Induced Agranulocytosis
This case report describes a previously healthy woman who developed severe facial cellulitis and ecthyma gangrenosum due to Pseudomonas aeruginosa following drug-induced agranulocytosis from carbimazole treatment.
DOI: 10.1001/archderm.142.12.1663 -
Acute cholestatic hepatitis along with agranulocytosis: A rare side effect of carbimazole
This case report describes a rare instance of acute cholestatic hepatitis and agranulocytosis in a 45-year-old female patient following treatment with carbimazole for hyperthyroidism, highlighting the need for awareness of potential severe side effects of antithyroid drugs.
DOI: 10.4103/1596-3519.64752 -
A Case of Antithyroid Drug-Induced Agranulocytosis Pre-Covid 19 Era
Carbimazole-induced agranulocytosis occurred within about 15 days at 45 mg/day in a relapsed Graves’ disease patient, with rapid recovery after stopping the drug and initiating antibiotics, underscoring the risk of early-onset neutropenia and need for prompt monitoring and patie…
DOI: 10.52916/jmrs204031 -
A case of antithyroid drug‐induced agranulocytosis from a second antithyroid drugs ( ATD ) administration in a relapsed Graves' disease patient who was tolerant to the first ATD treatment
This case report describes a 64-year-old female patient with relapsed Graves' disease who developed severe agranulocytosis after three weeks of treatment with carbimazole, despite previously tolerating methimazole for 72 months without adverse effects.
DOI: 10.1002/ccr3.1644 -
Diagnosis And Management Of Antithyroid Drug Induced Agranulocytosis
Agranulocytosis is a rare but life-threatening adverse effect of antithyroid drugs in Graves' disease; prompt drug cessation, antibiotics, and G-CSFs led to recovery in a 35-year-old woman, underscoring the need for early recognition and alternative hyperthyroid therapies.
DOI: 10.29103/micohedmed.v1i1.27 -
Antithyroid Drug-Induced Agranulocytosis: State of the Art on Diagnosis and Management
A comprehensive review of antithyroid drug–induced agranulocytosis, covering its definition, epidemiology, risk factors (including genetic associations), clinical presentation, diagnostic criteria, management (drug cessation, antibiotics, G-CSF in selected cases), prevention, an…
DOI: 10.1007/s40268-017-0172-1 -
Current trends in antithyroid drug treatment of Graves’ disease
A comprehensive 2016 review of Graves' disease medical management focused on antithyroid drugs (carbimazole/methimazole, propylthiouracil), dosing strategies, adjunctive therapies, adverse effects, pregnancy considerations, and emerging TRAb-targeted approaches, concluding that …
DOI: 10.1080/14656566.2016.1232388 -
Long-Term Treatment of Hyperthyroidism with Antithyroid Drugs: 35 Years of Personal Clinical Experience
Long-term antithyroid drug therapy, mainly methimazole, is effective and safe for hyperthyroidism, producing higher remission rates after withdrawal than conventional therapy and not inferior to radioiodine in Graves' disease, children, and toxic multinodular goiter.
DOI: 10.1089/thy.2019.0814